Drug intelligence / Profile preview

EB1003

Development stage: Unknown
Lead developer: Eden Biologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

EB1003 is a biosimilar monoclonal antibody candidate of ipilimumab, developed by Eden Biologics (formerly JHL Biotech). It is a recombinant human IgG1 monoclonal antibody that targets Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), a checkpoint molecule that down-regulates T-cell activation. By binding to CTLA-4, EB1003 blocks its interaction with ligands (CD80/CD86) on antigen-presenting cells, thereby maintaining T-cell activation and enhancing the immune system's ability to recognize and eliminate tumor cells. The drug is primarily being developed for the treatment of late-stage (metastatic) melanoma and is currently in early-stage clinical development.

Other names: ipilimumab biosimilar

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)

Beyond the preview

Go deeper on EB1003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EB1003.

Explore the full profile